Galantamine potentiates the neuroprotective effect of memantine against NMDA‐induced excitotoxicity
Open Access
- 11 January 2013
- journal article
- research article
- Published by Wiley in Brain and Behavior
- Vol. 3 (2), 67-74
- https://doi.org/10.1002/brb3.118
Abstract
The combination of memantine, an N‐methyl‐d‐aspartate (NMDA) receptor antagonist, with an acetylcholinesterase inhibitor (AChEI) is the current standard of care in Alzheimer's disease (AD). Galantamine, an AChEI currently marketed for the treatment of AD, exerts memory‐enhancing and neuroprotective effects via activation of nicotinic acetylcholine receptors (nAChRs). Here, we investigated the neuroprotective properties of galantamine in primary cultures of rat cortical neurons when given alone or in combination with memantine. In agreement with previous findings, we found that memantine was fully effective in reversing NMDA toxicity at concentrations of 2.5 and 5 μmol/L. Galantamine also completely reversed NMDA toxicity at a concentration of 5 μmol/L. The α7 and α4β2 nAChR antagonists, methyllycaconitine, and dihydro‐β‐erythroidine blocked the neuroprotective effect of galantamine, demonstrating the involvement of nAChRs. The combination of memantine with galantamine produced synergistic actions, such that full neuroprotective efficacy, was obtained at inactive concentrations of memantine (0.1 μmol/L) and galantamine (1 μmol/L). A similar potentiation was also observed when memantine was replaced with ifenprodil, suggesting a possible involvement of the NR2B subunit of the NMDA receptor. In summary, our study reports for the first time at a cellular level that memantine and galantamine interact on the same excitotoxic cascade and that the combination of these two drugs can result in a remarkable neuroprotective effect.Keywords
This publication has 31 references indexed in Scilit:
- Alzheimer's disease: strategies for disease modificationNature Reviews Drug Discovery, 2010
- Mechanisms of Neuroprotective Effects of Nicotine and Acetylcholinesterase Inhibitors: Role of α4 and α7 Receptors in NeuroprotectionJournal of Molecular Neuroscience, 2009
- Rationale for Combination Therapy With Galantamine and Memantine in Alzheimer's DiseaseThe Journal of Clinical Pharmacology, 2006
- The chemical biology of clinically tolerated NMDA receptor antagonistsJournal of Neurochemistry, 2006
- Protective effect of donepezil in primary-cultured rat cortical neurons exposed to N-methyl-d-aspartate (NMDA) toxicityEuropean Journal of Pharmacology, 2006
- Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studiesInternational Journal of Geriatric Psychiatry, 2005
- Involvement of calcineurin in the neurotoxic effects induced by amyloid‐beta and prion peptidesEuropean Journal of Neuroscience, 2003
- Mechanism of memantine block of NMDA‐activated channels in rat retinal ganglion cells: uncompetitive antagonism.Journal Of Physiology-London, 1997
- Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicityJournal of Neuroscience, 1992
- SELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASEThe Lancet, 1976